Sigachi Industries Limited has announced a significant R&D milestone with the successful advancement of a new Cystic Fibrosis (CF) Active Pharmaceutical Ingredients (APIs) combination, comprising Vanzacaftor, Tezacaftor, and Deutivacaftor. This development aligns with the company's strategy to expand its presence in complex, high-value specialty APIs, tapping into the global cystic fibrosis therapeutics market estimated to exceed USD 10 billion. Sigachi is exploring strategic collaborations for R&D and future commercial supply of these CF APIs. Subject to successful partnerships and market progression, the company estimates a revenue potential of approximately ₹250 crore per annum, commencing from Q4 FY2026–27. Lijo Chacko, Deputy Group CEO, stated that this milestone reflects the company's focused strategy of building depth in complex and differentiated APIs with long-term growth visibility. The CF API combination involves advanced chemistry and specialized reactions, presenting high technological complexity and significant barriers to entry. The innovator patent protection for Vanzacaftor extends until 2039, offering sustained commercial opportunity within the cystic fibrosis therapeutic space.
